Kite Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Kite Pharma (KITE) PT Raised to $120 at Canaccord Genuity
August 8, 2017 12:51 PM EDTCanaccord Genuity raised its price target on Kite Pharma (NASDAQ: KITE) to $120.00 (from $115.00) while maintaining a Buy rating.
Analyst John Newman with the coverage.
... MoreKite Pharma (KITE) Post Smaller Q2 Loss on Higher Revs
August 8, 2017 8:01 AM EDTKite Pharma (NASDAQ: KITE) reported Q2 EPS of ($1.50), $0.48 better than the analyst estimate of ($1.98). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $9.59 million.
"We've continued to make significant progress on key clinical and commercial milestones in the... More
